A recent Health Affairs blog post looks at what the U.S. is actually getting with such high drug prices.
The authors looked at prices for 46 new drugs approved in the U.S. in 2017.
“Of the 46 NMEs, 20 were found by at least one assessing agency to offer no or minor additional benefits over existing treatments,” the authors, Richard Frank, Jerry Avorn and Aaron Kesselheim, write. “Among those 20, there was disagreement across the agencies about three, leaving 17 drugs—nearly 37 percent of all those approved that year—with consistent agreement that they offered little or no added benefit.”
To read the full blog post, click here.